Why is 11β-hydroxy steroid dehydrogenase type 1 facing the endoplasmic reticulum lumen?: Physiological relevance of the membrane topology of 11β-HSD1

被引:59
|
作者
Odermatt, A
Atanasov, AG
Balazs, Z
Schweizer, RAS
Nashev, LG
Schuster, D
Langer, T
机构
[1] Univ Bern, Dept Clin Res, Dept Hypertens & Nephrol, CH-3010 Bern, Switzerland
[2] Univ Innsbruck, Inst Pharm, A-6020 Innsbruck, Austria
关键词
glucocorticoid receptor; 11 beta-hydroxysteroid dehydrogenase; cortisone; 7-ketocholesterol; hexose-6-phosphate dehydrogenase; membrane topology;
D O I
10.1016/j.mce.2005.11.040
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) is essential for the local activation of glucocorticoid receptors (GR). Unlike unliganded cytoplasmic GR, 11 beta-HSD1 is an endoplasmic reticulum (ER)-membrane protein with lumenal orientation. Cortisone might gain direct access to 11 beta-HSD1 by free diffusion across membranes, indirectly via intracellular binding proteins or, alternatively, by insertion into membranes. Membranous cortisol, formed by 11 beta-HSD1 at the ER-lumenal side, might then activate cytoplasmic GR or bind to ER-lumenal secretory proteins. Compartmentalization of 11 beta-HSD1 is important for its regulation by hexose-6-phosphate dehydrogenase (H6PDH), which regenerates cofactor NADPH in the ER lumen and stimulates oxoreductase activity. ER-lumenal orientation of 11 beta-HSD1 is also essential for the metabolism of the alternative substrate 7-ketocholesterol (7KC), a major cholesterol oxidation product found in atherosclerotic plaques and taken up from processed cholesterol-rich food. An 11 beta-HSD1 mutant adopting cytoplasmic orientation efficiently catalyzed the oxoreduction of cortisone but not 7KC, indicating access to cortisone from both sides of the ER-membrane but to 7KC only from the lumenal side. These aspects may be relevant for understanding the physiological role of 11 beta-HSD1 and for developing therapeutic interventions to control glucocorticoid reactivation. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:15 / 23
页数:9
相关论文
共 50 条
  • [1] Medicinal Chemistry of Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)
    Scott, James S.
    Goldberg, Frederick W.
    Turnbull, Andrew V.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4466 - 4486
  • [2] Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
    Sun, Daqing
    Wang, Zhulun
    Di, Yongmei
    Jaen, Juan C.
    Labelle, Marc
    Ma, Ji
    Miao, Shichang
    Sudom, Athena
    Tang, Liang
    Tomooka, Craig S.
    Tu, Hua
    Ursu, Stefania
    Walker, Nigel
    Yan, Xuelei
    Ye, Qiuping
    Powers, Jay P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (12) : 3513 - 3516
  • [3] Synthesis and optimization of arylsulfonylpiperazines as a novel class of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
    Sun, Daqing
    Wang, Zhulun
    Cardozo, Mario
    Choi, Rebekah
    DeGraffenreid, Michael
    Di, Yongmei
    He, Xiao
    Jaen, Juan C.
    Labelle, Marc
    Liu, Jinsong
    Ma, Ji
    Miao, Shichang
    Sudom, Athena
    Tang, Liang
    Tu, Hua
    Ursu, Stefania
    Walker, Nigel
    Yan, Xuelei
    Ye, Qiuping
    Powers, Jay P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (05) : 1522 - 1527
  • [4] Synthesis and biological evaluation of picolinamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
    Ryu, Je Ho
    Kim, Shinae
    Han, Hye Young
    Son, Hyun Joo
    Lee, Hyun Jung
    Shin, Young Ah
    Kim, Jae-Sun
    Park, Hyeung-geun
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (03) : 695 - 700
  • [5] Inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1) by carbenoxolone (CBX) in obese Zucker rats
    Chatelain, R
    Odorico, L
    Schwarztkopf, C
    Battle, B
    Stevens, D
    Dardik, B
    Laurent, D
    Sun, DM
    Burkey, B
    Hughes, T
    [J]. DIABETES, 2003, 52 : A326 - A326
  • [6] Effect of Glucocorticoid and 11β-Hydroxysteroid-Dehydrogenase Type 1 (11β-HSD1) in Neurological and Psychiatric Disorders
    Dodd, Seetal
    Skvarc, David R.
    Dean, Olivia M.
    Anderson, Anna
    Kotowicz, Mark
    Berk, Michael
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (05): : 387 - 398
  • [7] Discovery of Adamantyl Ethanone Derivatives as Potent 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors
    Su, Xiangdong
    Pradaux-Caggiano, Fabienne
    Thomas, Mark P.
    Szeto, Michelle W. Y.
    Halem, Heather A.
    Culler, Michael D.
    Vicker, Nigel
    Potter, Barry V. L.
    [J]. CHEMMEDCHEM, 2010, 5 (07) : 1026 - 1044
  • [8] Recent progress in 11-β-hydroxysteroid dehydrogenase type 1 (11-β-HSD1) inhibitor development
    Barf, Tjeerd
    Williams, Meredith
    [J]. DRUGS OF THE FUTURE, 2006, 31 (03) : 231 - 243
  • [9] 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors Still Improve Metabolic Phenotype in Male 11β-HSD1 Knockout Mice Suggesting Off-Target Mechanisms
    Harno, Erika
    Cottrell, Elizabeth C.
    Yu, Alice
    DeSchoolmeester, Joanne
    Gutierrez, Pablo Morentin
    Denn, Mark
    Swales, John G.
    Goldberg, Fred W.
    Bohlooly-Y, Mohammad
    Andersen, Harriet
    Wild, Martin J.
    Turnbull, Andrew V.
    Leighton, Brendan
    White, Anne
    [J]. ENDOCRINOLOGY, 2013, 154 (12) : 4580 - 4593
  • [10] Functional Effects of Polymorphisms in the Human Gene Encoding 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1): A Sequence Variant at the Translation Start of 11β-HSD1 Alters Enzyme Levels
    Malavasi, Elise L. V.
    Kelly, Val
    Nath, Nikita
    Gambineri, Alessandra
    Dakin, Rachel S.
    Pagotto, Uberto
    Pasquali, Renato
    Walker, Brian R.
    Chapman, Karen E.
    [J]. ENDOCRINOLOGY, 2010, 151 (01) : 195 - 202